Testosterone Enanthate in Adults 65 and Older: Safety Profile, Risks, and Monitoring

Why Geriatric Safety Deserves Separate Attention

Men aged 65 and older metabolize testosterone enanthate against a backdrop of declining renal function, higher baseline cardiovascular risk, and polypharmacy that younger men rarely face. The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and showed improvements in sexual function, vitality, and walking distance over 12 months of transdermal testosterone gel therapy 1. Those benefits were real, but the trial was not powered to detect rare cardiovascular events.

That gap matters. The Endocrine Society's 2018 clinical practice guideline recommends a shared decision-making approach for men over 65, weighing symptomatic benefit against individualized risk. Testosterone enanthate's intramuscular delivery produces higher peak-to-trough swings than gels, which can amplify hematocrit rises and blood pressure variability in older patients. These pharmacokinetic differences make geriatric-specific monitoring protocols non-optional.

Cardiovascular Risk: What the Evidence Actually Shows

The cardiovascular question dominated TRT prescribing for a decade. A clear answer arrived in 2023. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine, randomized men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk to transdermal testosterone or placebo 2. The primary endpoint of major adverse cardiovascular events (MACE) was non-inferior in the testosterone arm (hazard ratio 0.96 to 95% CI 0.78-1.17).

That result was reassuring but not a blank check. TRAVERSE participants received carefully titrated doses with hematocrit monitoring and protocol-driven dose holds. Real-world prescribing in older men often lacks that discipline. The trial also identified a statistically significant increase in atrial fibrillation (HR 1.26), pulmonary embolism (HR 1.92), and acute kidney injury (HR 1.28) in the testosterone group 2.

For men 65 and older receiving testosterone enanthate specifically, the intramuscular route's supraphysiologic peaks in the 48 to 72 hours post-injection may pose a higher transient risk for arrhythmia and blood pressure elevation than the steady-state delivery seen in TRAVERSE's gel-based protocol. The American Urological Association (AUA) recommends that clinicians inform older patients about these findings and obtain baseline cardiovascular evaluation before initiating therapy.

Polycythemia: The Most Common Lab Abnormality

Testosterone stimulates erythropoiesis. That effect is dose-dependent and more pronounced in older men. A secondary analysis of the T-Trials found that 8.5% of testosterone-treated men developed a hematocrit above 54% compared to 0.4% on placebo 3. In men over 65, lower plasma volume and age-related renal erythropoietin sensitivity compound this risk.

The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 to 6 months after initiation, and then annually 3. If hematocrit exceeds 54%, the recommendation is to stop testosterone until it falls below 50%, then resume at a reduced dose. For testosterone enanthate, practical dose reduction means dropping from 100 mg weekly to 75 mg, or extending the injection interval from 7 to 10 days.

Phlebotomy is sometimes used as a bridge, but it treats the lab number without addressing the underlying supraphysiologic exposure. Dose adjustment should come first.

Renal Function and Fluid Retention

Glomerular filtration rate declines by roughly 1 mL/min/year after age 40, meaning the average 75-year-old has a GFR approximately 35 mL/min lower than a 40-year-old 4. Testosterone enanthate does not require renal dose adjustment because it is metabolized hepatically, but its sodium-retaining effect becomes clinically relevant when renal clearance of sodium and water is already compromised.

Peripheral edema, weight gain of 2 to 4 kg, and worsening of pre-existing heart failure are reported in post-marketing surveillance. The FDA prescribing information for testosterone enanthate lists edema as a recognized adverse reaction and advises caution in patients with cardiac, renal, or hepatic disease. For older men taking loop diuretics or ACE inhibitors, adding testosterone can shift fluid balance enough to require medication re-titration.

Baseline and quarterly weight checks, lower extremity edema assessment, and BNP measurement in men with known heart failure are practical additions to the monitoring routine.

Drug Interactions in Polypharmacy Patients

The median number of chronic medications in U.S. adults aged 65 to 79 is five 5. Testosterone enanthate interacts with several commonly prescribed drug classes.

Warfarin and direct oral anticoagulants. Testosterone increases the effect of warfarin by altering hepatic synthesis of clotting factors. Case reports document INR rises from therapeutic range to above 5.0 within weeks of starting TRT 6. INR should be checked within 1 to 2 weeks of initiating testosterone in any patient on warfarin, and warfarin dose reduced preemptively by 10 to 25%. Data on interactions with apixaban and rivarelbaan are limited but theoretically lower risk because these agents bypass the vitamin K pathway.

Insulin and oral hypoglycemics. Testosterone improves insulin sensitivity. The T-Trials documented a mean reduction in fasting glucose of 5 mg/dL in testosterone-treated men 1. In men on sulfonylureas or insulin, this effect may provoke hypoglycemia. Glucose monitoring should increase in frequency during the first 3 months.

Corticosteroids. Concurrent use with corticosteroids increases the risk of edema. The combination is specifically flagged in the FDA label. If systemic corticosteroids cannot be discontinued, sodium restriction and diuretic adjustment may be needed.

5-alpha reductase inhibitors. Finasteride and dutasteride block conversion of testosterone to dihydrotestosterone. Some older men take these for benign prostatic hyperplasia. The combination is not contraindicated, but it alters the testosterone-to-DHT ratio and may blunt androgenic effects on prostate tissue while preserving anabolic and mood-related benefits. PSA interpretation becomes more complex because 5-alpha reductase inhibitors lower PSA by approximately 50%.

Prostate Safety in Older Men

The relationship between testosterone therapy and prostate cancer risk has been studied extensively. The TRAVERSE trial's prostate substudy found no significant difference in prostate cancer incidence between testosterone and placebo groups over a median follow-up of 33 months (HR 0.97 to 95% CI 0.51-1.84) 7. The American Urological Association's 2018 guideline states that testosterone therapy does not appear to increase the risk of prostate cancer in hypogonadal men.

Standard monitoring includes a digital rectal exam and PSA measurement at baseline, at 3 to 6 months, and annually thereafter. A PSA rise of more than 1.4 ng/mL within any 12-month period, or a velocity consistently above 0.75 ng/mL per year, should prompt urological referral regardless of absolute PSA value.

Men with untreated, locally advanced, or metastatic prostate cancer should not receive testosterone enanthate. For men with a history of successfully treated localized prostate cancer and undetectable PSA, the Endocrine Society guideline permits testosterone therapy after a shared decision-making discussion with urology 3. A waiting period of at least 1 year post-treatment is commonly applied, though evidence supporting a specific interval remains limited.

Falls, Bone Density, and Physical Function

Falls are the leading cause of injury death in adults over 65, according to CDC data. Testosterone's effect on fall risk is theoretically protective through increased muscle mass and bone mineral density, but the clinical evidence is mixed.

The T-Trials' Physical Function Trial showed that testosterone improved self-reported walking ability and 6-minute walking distance by a median of 33 meters compared to placebo 1. The Bone Trial substudy demonstrated increased volumetric bone mineral density at the spine and hip after 12 months 8. Estimated bone strength also improved.

These gains did not translate into a proven reduction in fractures, partly because the T-Trials were too small and too short to capture fracture endpoints. A systematic review published in the Journal of Clinical Endocrinology and Metabolism noted that testosterone therapy consistently increases lumbar spine BMD by 3 to 8% over 12 to 36 months but called fracture data "insufficient for conclusions" 9.

One practical concern: intramuscular testosterone enanthate requires injection-site muscle mass and subcutaneous tissue adequate for IM delivery. Sarcopenic older men with significant muscle wasting may have injection-site complications or erratic absorption. The ventrogluteal site is preferred over the dorsogluteal in geriatric patients because of its distance from the sciatic nerve and greater muscle depth in deconditioned individuals.

Dose Selection and Titration Strategy

"Start low and go slow" applies directly here. The Endocrine Society guideline recommends titrating testosterone to mid-normal range (400-600 ng/dL) rather than the upper normal range often targeted in younger men 3.

For testosterone enanthate in men 65 and older, a practical approach:

• Starting dose: 50 to 75 mg intramuscularly every 7 days, or 100 mg every 14 days
• First lab check: trough testosterone, hematocrit, PSA, and hepatic panel at 6 to 8 weeks
• Dose adjustment: increase by 25 mg per injection if trough testosterone remains below 350 ng/dL and symptoms persist
• Ceiling: most geriatric patients stabilize between 75 and 125 mg weekly. Doses above 150 mg weekly are rarely justified in this age group
• Peak measurement: if polycythemia develops despite trough levels in range, check a mid-cycle (day 3 or 4) testosterone level to assess peak exposure

Splitting the dose into twice-weekly injections (e.g., 37.5 mg twice weekly instead of 75 mg once weekly) reduces peak-to-trough fluctuation by approximately 40%, which may lower hematocrit spikes and improve mood stability. This approach requires patient willingness to inject more frequently. For older men with limited dexterity or caregiver-dependent injection schedules, weekly dosing may be more realistic.

Dr. Shalender Bhasin, principal investigator of the T-Trials, has noted: "The goal in older men is to restore testosterone to the low-normal range, not to maximize it. The therapeutic window narrows with age, and the risk of erythrocytosis rises steeply above mid-normal concentrations" 1.

When to Consider Deprescribing

Not every older man who starts testosterone should remain on it indefinitely. The Endocrine Society guideline recommends periodic reassessment of symptoms and treatment goals 3. Practical triggers for deprescribing include:

• Resolution of the original symptoms (fatigue, low libido, decreased muscle strength)
• New diagnosis of heart failure with reduced ejection fraction
• Hematocrit persistently above 50% despite dose reduction
• New diagnosis of hormone-sensitive prostate cancer
• Patient preference, especially if injection burden exceeds perceived benefit
• Transition to palliative or comfort-focused care goals

Abrupt discontinuation of exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. In younger men, recovery of endogenous production is expected over weeks to months. In men over 65, endogenous recovery may be incomplete or absent because age-related Leydig cell decline predates TRT initiation 10. Tapering over 4 to 8 weeks, with symptom monitoring and repeat testosterone measurement at 4 and 12 weeks post-cessation, allows the clinical team to distinguish between withdrawal symptoms and return of baseline hypogonadism.

Dr. Alvin Matsumoto, a geriatric endocrinologist and co-author of the Endocrine Society guideline, has stated: "In older men, the question is not only whether to start testosterone, but whether to continue it. Annual reassessment should be standard practice" 3.

Monitoring Schedule Summary

A structured monitoring protocol reduces adverse events in older men on testosterone enanthate. The following schedule aligns with Endocrine Society and AUA recommendations:

Baseline (before first injection): two morning testosterone levels, hematocrit, PSA, lipid panel, fasting glucose or HbA1c, hepatic function panel, digital rectal exam, bone density (DXA) if osteoporosis risk factors are present, and cardiovascular risk assessment.

6 to 8 weeks: trough testosterone, hematocrit, PSA.

3 to 6 months: trough testosterone, hematocrit, PSA, fasting glucose, hepatic function, weight and edema check, symptom reassessment using a validated instrument (e.g., AMS scale).

Annually thereafter: all of the above plus lipid panel, DXA if baseline showed osteopenia or osteoporosis, and a formal deprescribing discussion documented in the chart.

Hematocrit above 54% at any time point requires immediate dose hold. PSA velocity above 0.75 ng/mL per year or absolute rise above 1.4 ng/mL within 12 months triggers urology referral.